Evidence map›Paper›PMID 40195473›Full record

ArticleScientific reports2025

Dexamethasone: a double-edged sword in the treatment of osteoarthritis.

Karyna Tarasova, Maria Belen Arteaga, Angkana Kidtiwong, Sinan Gueltekin, Andrea Bileck, Christopher Gerner, Iris Gerner, Florien Jenner

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Karyna TarasovaVETERM, Equine Surgery Unit, Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria.
Maria Belen ArteagaVETERM, Equine Surgery Unit, Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria.
Angkana KidtiwongVETERM, Equine Surgery Unit, Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria.
Sinan GueltekinVETERM, Equine Surgery Unit, Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria.
Andrea BileckDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
Christopher GernerDepartment of Analytical Chemistry, Faculty of Chemistry, University of Vienna, Vienna, Austria.
Iris GernerVETERM, Equine Surgery Unit, Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria.
Florien JennerVETERM, Equine Surgery Unit, Centre for Equine Health and Research, Department for Small Animals and Horses, University of Veterinary Medicine Vienna, Vienna, Austria. florien.jenner@vetmeduni.ac.at.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glucocorticoids are widely used to manage osteoarthritis (OA) symptoms, but long-term safety concerns exist. This study investigates the therapeutic potential of dexamethasone (DEX) and triamcinolone acetonide (TA) in chondrocytes, evaluating their anti-inflammatory effects and potential detrimental actions. This study evaluated the effects of DEX and TA on the expression of pro-inflammatory genes in inflamed chondrocytes. In addition, the effects of DEX treatment on chondrocytes were analyzed using next-generation sequencing, high-resolution mass spectrometry, proliferation and metabolic rate, wound healing capacity and senescence-associated B-galactosidase assays. A single therapeutic dose of DEX (40nM) effectively reduced the expression of inflammatory genes in chondrocytes, while TA showed no such effect. DEX significantly reduced inflammation but also ECM production in inflamed chondrocytes. At 24 h, DEX treatment led to 168 differentially expressed genes (DEGs) compared to untreated inflamed cells, decreasing to 5 DEGs by 48 h, indicating a rapidly diminishing anti-inflammatory effect. Conversely, the difference between DEX-treated and healthy cells increased over time, from 666 DEGs at 24 h to 1317 DEGs at 48 h. Pathway analysis revealed potential disruptions in cell cycle, mitosis, and ECM homeostasis in DEX-treated cells compared to both healthy and inflamed controls. Interestingly, repeated DEX administration at both a therapeutic (40nM) and a high dose (1µM) induced senescence in healthy cells but not in inflamed cells. In contrast, repeated high-dose DEX reduced apoptosis marker Caspase 3/7 in inflamed but not healthy cells. Despite the transient suppression of inflammation achieved with DEX treatment, the observed decrease in ECM production and induction of senescence in healthy chondrocytes at therapeutic doses, along with apoptosis in inflamed cells at higher doses, underscore the need for caution in its intra-articular administration.

Indexed as

Anti-Inflammatory AgentsChondrocytesDexamethasoneOsteoarthritisApoptosisCell ProliferationCells, CulturedCellular SenescenceGene Expression ProfilingGene Expression RegulationGlucocorticoidsHumansInflammationTriamcinolone AcetonideAnti-Inflammatory AgentsDexamethasoneGlucocorticoidsTriamcinolone AcetonideApoptosisDexamethasoneGlucocorticoidsOsteoarthritisSenescenceTriamcinolone

Identifiers

PMID40195473
PMCPMC11976973

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.